Asymchem Laboratories Tian Jin Co Ltd (002821) - Total Assets

Latest as of December 2025: CN¥20.28 Billion CNY ≈ $2.97 Billion USD

Based on the latest financial reports, Asymchem Laboratories Tian Jin Co Ltd (002821) holds total assets worth CN¥20.28 Billion CNY (≈ $2.97 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Asymchem Laboratories Tian Jin Co Ltd net assets for net asset value and shareholders' equity analysis.

Asymchem Laboratories Tian Jin Co Ltd - Total Assets Trend (2011–2025)

This chart illustrates how Asymchem Laboratories Tian Jin Co Ltd's total assets have evolved over time, based on quarterly financial data.

Asymchem Laboratories Tian Jin Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2025)

Asymchem Laboratories Tian Jin Co Ltd's total assets of CN¥20.28 Billion consist of 56.7% current assets and 43.3% non-current assets.

Asset Category Amount (CNY) % of Total Assets
Cash & Equivalents CN¥0.00 31.2%
Accounts Receivable CN¥1.95 Billion 9.6%
Inventory CN¥1.47 Billion 7.3%
Property, Plant & Equipment CN¥0.00 0.0%
Intangible Assets CN¥421.80 Million 2.1%
Goodwill CN¥146.18 Million 0.7%

Asset Composition Trend (2011–2025)

This chart illustrates how Asymchem Laboratories Tian Jin Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Asymchem Laboratories Tian Jin Co Ltd market cap and net worth.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Asymchem Laboratories Tian Jin Co Ltd's current assets represent 56.7% of total assets in 2025, an increase from 52.7% in 2011.
  • Cash Position: Cash and equivalents constituted 31.2% of total assets in 2025, up from 21.9% in 2011.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 3.0% in 2011.
  • Asset Diversification: The largest asset category is accounts receivable at 9.6% of total assets.

Asymchem Laboratories Tian Jin Co Ltd Competitors by Total Assets

Key competitors of Asymchem Laboratories Tian Jin Co Ltd based on total assets are shown below.

Company Country Total Assets
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
USA $7.59 Billion
Summit Therapeutics PLC
NASDAQ:SMMT
USA $261.73 Million
Argen-X
F:1AE
Germany €7.18 Billion
Metsera, Inc. Common Stock
NASDAQ:MTSR
USA $639.66 Million
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
China CN¥3.06 Billion
R&G PharmaStudies Co. Ltd. A
SHE:301333
China CN¥2.31 Billion
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
China CN¥819.45 Million
Innovita Biological Technology Co. Ltd. A
SHG:688253
China CN¥2.16 Billion

Asymchem Laboratories Tian Jin Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 5.85 6.46 4.57
Quick Ratio 5.10 5.77 3.66
Cash Ratio 0.00 0.00 0.00
Working Capital CN¥9.54 Billion CN¥9.34 Billion CN¥3.12 Billion

Asymchem Laboratories Tian Jin Co Ltd - Advanced Valuation Insights

This section examines the relationship between Asymchem Laboratories Tian Jin Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.50
Latest Market Cap to Assets Ratio 0.30
Asset Growth Rate (YoY) 5.1%
Total Assets CN¥20.28 Billion
Market Capitalization $6.12 Billion USD

Valuation Analysis

Below Book Valuation: The market values Asymchem Laboratories Tian Jin Co Ltd's assets below their book value (0.30x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Asymchem Laboratories Tian Jin Co Ltd's assets grew by 5.1% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Asymchem Laboratories Tian Jin Co Ltd (2011–2025)

The table below shows the annual total assets of Asymchem Laboratories Tian Jin Co Ltd from 2011 to 2025.

Year Total Assets Change
2025-12-31 CN¥20.28 Billion
≈ $2.97 Billion
+5.13%
2024-12-31 CN¥19.29 Billion
≈ $2.82 Billion
-2.42%
2023-12-31 CN¥19.77 Billion
≈ $2.89 Billion
+8.38%
2022-12-31 CN¥18.24 Billion
≈ $2.67 Billion
+20.34%
2021-12-31 CN¥15.16 Billion
≈ $2.22 Billion
+111.04%
2020-12-31 CN¥7.18 Billion
≈ $1.05 Billion
+91.06%
2019-12-31 CN¥3.76 Billion
≈ $550.02 Million
+18.00%
2018-12-31 CN¥3.19 Billion
≈ $466.12 Million
+20.78%
2017-12-31 CN¥2.64 Billion
≈ $385.91 Million
+7.87%
2016-12-31 CN¥2.44 Billion
≈ $357.77 Million
+92.28%
2015-12-31 CN¥1.27 Billion
≈ $186.06 Million
+20.16%
2014-12-31 CN¥1.06 Billion
≈ $154.84 Million
+15.88%
2013-12-31 CN¥913.19 Million
≈ $133.63 Million
+10.29%
2012-12-31 CN¥828.00 Million
≈ $121.16 Million
+3.45%
2011-12-31 CN¥800.41 Million
≈ $117.13 Million
--

About Asymchem Laboratories Tian Jin Co Ltd

SHE:002821 China Biotechnology
Market Cap
$6.12 Billion
CN¥41.82 Billion CNY
Market Cap Rank
#3135 Global
#445 in China
Share Price
CN¥125.56
Change (1 day)
-0.98%
52-Week Range
CN¥80.40 - CN¥129.49
All Time High
CN¥358.21
About

Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, incl… Read more